Immunity Project is a non-profit initiative of Flow Pharma, Inc. dedicated to developing a free HIV vaccine. Flow Pharma, Inc. is a for-profit company that was founded in 2002 to develop drug delivery technologies. The company is focused on developing technologies related to manufacturing and formulation of biodegradable microspheres. The company has spent over $1 million dollars creating and acquiring intellectual property related to its biodegradable microsphere technology. Immunity Project uses this intellectual property on a perpetual, royalty free basis in the development and eventual worldwide distribution of its free HIV vaccine.
While Flow Pharma is a for profit entity, Immunity Project is a 100% non-profit initiative. Immunity Project was created in September 2013 as a fiscally sponsored project of the HIV/AIDS-focused 501(c)(3) organization, Until There’s A Cure Foundation. All donations to Immunity Project, including all of the funds donated via crowd funding, are processed and managed by Until There’s A Cure. Until There’s A Cure retains 1% of total dollars donated to cover management and overhead and makes the rest of the funds available to Immunity Project solely to further development of the free HIV vaccine. Flow Pharma set things up this way because the company develops unique drug delivery technology that has both for profit and non-profit potential. The for-profit potential includes delivery of antibiotics and other vaccines. The non-profit potential is Immunity Project’s free HIV vaccine.
Should the Immunity Project free HIV vaccine development effort prove successful, Flow Pharma, Inc. will benefit from validation of its drug delivery technology. In addition to their roles with Immunity Project, Dr. Reid Rubsamen and Naveen Jain are both shareholders and serve on the board of directors of Flow Pharma, Inc.
With regards to our advisors, Dr. Bruce Walker and Dr. Salim Abdool Karim were long-term collaborators. However, when Immunity Project launched its crowd funding campaign, they both requested to be removed from the project’s website and materials, which was done promptly. We have different opinions on how to move forward with this research. Going forward, upon completion of it’s experiments, Immunity Project will release its data in pre-print form along with submission for peer review.
If you have any questions about Immunity Project, please don’t hesitate to contact us at email@example.com.